Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Prostatic Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Disease Progression 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Fulvestrant 5serabelisib 2sapanisertib 2ribociclib 2palbociclib 2Paclitaxel 2Letrozole 2Irinotecan 2Gemcitabine 2Carboplatin 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1sotorasib 1pembrolizumab 1olaparib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1ceralasertib 1cemiplimab 1capivasertib 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × tivozanib × 1 year × Clear all
NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡